DMARDs & Immunosuppressives

FDA Approves Subcutaneous Tocilizumab for Ages 2–17

October 29, 2018 • By Michele B. Kaufman, PharmD, BCGP

Plaque Psoriasis Treatments: BMS-986165 Promising & Adalimumab Biosimilar Demonstrates Equivalence

October 22, 2018 • By Michele B. Kaufman, PharmD, BCGP

Revised Application Expected for IV Meloxicam; Plus EU Approves Tildrakizumab

October 9, 2018 • By Michele B. Kaufman, PharmD, BCGP

More Evidence TNF Inhibitors Raise Risk of Peripheral Neuropathy

October 8, 2018 • By Megan Brooks

TNFi Exposure in Utero

September 26, 2018 • By Arthritis & Rheumatology

Placebos: Their Underappreciated Impact in Pharmaceutical Trials

Placebos: Their Underappreciated Impact in Pharmaceutical Trials

September 20, 2018 • By Terence W. Starz, MD, Theodore Pincus, MD, On Behalf Of The ARHP Practice Committee

Piclidenoson in Trials for Psoriasis & RA; Plus Duzallo Approved in Europe

September 18, 2018 • By Michele B. Kaufman, PharmD, BCGP

Tanezumab Promising for OA Pain; Plus, Filgotinib Investigated for Psoriatic Arthritis

August 15, 2018 • By Michele B. Kaufman, PharmD, BCGP

Long-Term Apremilast Promising for Psoriatic Arthritis

July 27, 2018 • By Michele B. Kaufman, PharmD, BCGP

Upadacitinib Promising for RA Patients

July 23, 2018 • By Michele B. Kaufman, PharmD, BCGP